Approximately 70% of patients show an initial response to VEGF TKIs, but patients eventually acquire resistance and the disease progresses as the tumor develops evasive mechanisms in response to VEGF TKI [3, 4]. The gene discussed is VEGFA; the disease is neoplasm.